drugset / Trial / NCT04373369
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Phase 2
Terminated
11 enrolled
Washington University School of Medicine
Xcovery Holdings, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine whether adding vorolanib to atezolizumab will improve the length of time that participants are cancer-free after receiving standard chemotherapy.
Timeline
- Start
- 2020-10-07
- Primary completion
- 2022-08-18
- Completion
- 2025-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | CM082 | Unknown | 200 mg | Oral |